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Background
For the development of biosimilar monoclonal antibo-
dies or related substances containing the IgG Fc part it
is mandatory to fully compare immunological properties
between originator and biosimilar in a “comparability
exercise” [1]. The important Fc associated functions to
mediate antibody dependent cellular cytotoxicity
(ADCC) and complement dependent cytotoxicity (CDC)
need to be characterized using both the active substance
of the biosimilar and the comparator [2,3]. For testing
anti TNFalpha antibodies target cells with stable expres-
sion of membrane TNFalpha (mTNFalpha) is required.
Further prerequisites are test systems facilitating analysis
with high precision and accuracy.
Materials and methods
We generated a human transgenic NK-cell line
(YTE756.V#26, effector cell line) with stable expression
of Fc gamma-receptor IIIA (CD16, high affinity variant,
valine at position 159) and stable functional characteris-
tics to replace primary effector cells in ADCC assays.
Target cells for ADCC and CDC assays were genetically
modified for stable expression of mTNFalpha without
the capability to release soluble TNFalpha. Both target
and effector cells were generated using retroviral vectors
to facilitate high and stable transgene expression. Vector
particles were generated by transient transfection of
293T cells with plasmids encoding gag, pol/env and an
expression plasmid containing the packaging region and
the sequences of promotor and the transgenes, i.e. selec-
tion marker and gene of interest. Multiple gene expres-
sion was achieved either by using a bicistronic design
enabling transcription from two promotor sequences, or
by using an internal ribosomal entry site. Transduction
of cells in log phase was followed by a selection of
transduced cells and clonal selection by limiting dilu-
tion. Cell clones were expanded for primary and second-
ary cell banks and further characterised with regard to
transgene expression and functional characteristics.
The more complex ADCC assays were developed
employing design of experiments (DoE). To show assay
suitability goodness of fit, ratio of upper to lower asymp-
tote, slope and parallelism was determined for each dose-
response curve compared to a standard. Hypo- and hyper-
potent samples (50%, 100%, 150% and 200% potency) of
Adalimumab and Infliximab were analysed in both ADCC
and CDC assays to determine accuracy and linearity of
each method.
For ADCC assays HT1080 mTNFalpha+ cells were
seeded into 96-well plates 18 -20 h before start of the
assay. Anti TNFalpha dilution series were performed in
separate plates and transferred into the assay plate
together with YTE756.V#26 effector cells at an E:T ratio
of 10:1 using the effectors cell medium as assay medium.
After an incubation time of 17 ± 1 h effector cells were
washed from the adherent target cells. Quantification of
residual target cells was performed by staining with XTT
and photometric measurement. Each assay consists of
standard (the biosimilar) and sample (originator) concen-
trations ranging from 1000 to 4.69 ng/ml in duplicates.
Comparison of dose-response curves in a 4 PL model
and determination of potency was performed using PLA
software (Stegmann Systems).
For CDC assays CHO mTNFalpha+ cells were seeded
into 96 well plates 20 - 25 h before start of the assay. Anti-
body dilution series were transferred into the assay plate
using cell culture medium containing 20% native human
serum pool. After an incubation time of 2 ± 0.5 h medium
non-adherent cells were removed by washing the MTP.
Quantification of residual cells was performed as described
for ADCC assays. Each assay consists of standard and
sample (originator or accuracy item) concentrations* Correspondence: Carsten.Lindemann@eufets.com
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ranging from 5000 to 130 ng/ml in duplicates. Compari-
son of dose-response curves in a 4 PL model and determi-
nation of the relative potency was performed using PLA
software.
Originator batches and the biosimilar were analysed by
monosaccharide and sialic acid analysis, N-glycan profiling
by MALDI-MS (permethylated glycans) and by HILIC-
HPLC. N-Glycosylation site determination was done by
MALDI and/or LC-ESI-MS and MS/MS (1 digestion).
Results
Both ADCC and CDC assays show good accuracy (rela-
tive accuracy < 15%) and linearity (r squared < 0.97).
Precision of CDC assays (CV < 8%) was better than that
of the more complex ADCC assays (< 15%). Due to the
distinctly lower actitivity of Adalimumab compared to
that of Infliximab we evaluated the most influential fac-
tor for gaining a high asymptote ratio by DoE. The incu-
bation time was shown to be most important compared
to other factors as effector to target cell ratio and fetal
bovine serum content.
We analysed different batches of originators and a bio-
similar candidate molecule for functional variability in
ADCC and CDC assays (Table 1). In CDC assays (n = 3)
the three originator batches of Adalimumab showed
comparable potency in between batches and compared to
the biosimilar. A higher variability of the originators was
found in ADCC assays (n = 6) besides the potency was
higher than that of the Adalimumab biosimilar.
Major differences between originators with regard to
glycosylation were not found. The biosimilar showed a
high galactose content and consequently a higher per-
centage of galactosylated glycan structures than the
originators.
Conclusions
In summary we show the suitability of an ADCC potency
assay for investigation of functional comparability of Ada-
limumab and biosimilar candidate substances. Differences
between biosimilar and originators in glycosylation might
contribute to differences found in the ADCC potency
assay but not with the CDC potency assay.
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Table 1 Relative potency (compared to biosimilar) of
originators in ADCC and CDC assays
Assay Originator Relative potency CV
ADCC 2 140% 9.9%
3 141% 11.1%
4 135% 16.8%
CDC 2 92% 15.1%
3 89% 10.2%
4 89% 16.7%
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